Developer docs
API playgroundTry for free, no card

Search company profiles

Pharos Capital Partners

Full company profile

uuid0000bx4

Namestring
Pharos Capital Partners
Legal namestring
Pharos Capital Group, LLC
Websiteurl
pharosfunds.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Pharos Capital Partners is a Dallas-based, physician-founded private equity firm established in 1998 by Dr. Kneeland Youngblood, a former ER physician, and Bob Crants. Since 2013 the firm has operated as a dedicated healthcare-only investor, deploying $25 million to $50 million per transaction into established U.S. healthcare companies that serve rural, urban, and tribal underserved communities, with stated impact measured against GIIN IRIS+ healthcare metrics and six UN Sustainable Development Goals. The firm manages $1.5 billion+ in assets across five fund vintages (Pharos Capital Partners I, II, III, III-A, and IV/IV-A) and has invested in 53+ portfolio companies spanning behavioral health, dialysis and renal care, hospice and home health, primary care, medical devices, surgical services, and healthcare staffing, collectively operating 1,600+ care locations across all 50 states.

The firm's core "products" are its portfolio operating companies rather than a single technology platform; selected platforms include FasPsych (telepsychiatry), Sanderling Renal Services and Renal Care 360° (dialysis, tele-nephrology, and ML-assisted chronic kidney disease management), RhythMedix (wearable cardiac ECG monitoring with 4G connectivity), Complete Health (Medicare value-based primary care), Beacon Specialized Living Services and The Family Treatment Network (behavioral health and developmental disability services), THEMA Health Services (hospice, home health, palliative care), Vantage Surgical Solutions (mobile cataract surgery), and Tribal Health (staffing and consulting for Native American communities across 18 states). Pharos's primary technology asset at the firm level is a proprietary impact-measurement methodology verified by independent consultants against all 14 GIIN IRIS+ healthcare metrics; at the portfolio level, Renal Care 360° applies machine learning to identify vulnerable CKD and ESKD patients for early intervention.

Pharos generates revenue through conventional private equity fund economics, earning management fees on committed or invested capital across its fund vintages and carried interest on realized exits (notable realizations include MOTION PT Group in 2023 and TechLab, Inc. in 2022). The firm does not disclose specific fee rates or revenue figures; pricing and fund terms are negotiated bilaterally with limited partners including foundations, family offices, and institutional investors. Distribution is relationship-driven, supported by offices in Dallas, Nashville, Baltimore, and Silicon Valley, a dedicated investor portal, a corporate website, and a LinkedIn presence, with deal sourcing directed toward healthcare founders and operators and partnership engagement with payors, hospitals, health systems, and governmental agencies serving underserved populations.

Short descriptiontext

Pharos Capital Partners is a Dallas-based, physician-founded private equity firm that invests $25-$50 million per deal in U.S. healthcare companies serving rural, urban, and tribal underserved communities, managing $1.5B+ across five fund vintages and 53+ portfolio companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDallas, United States
HQ citystring
Dallas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare private equity, private equity funds, healthcare investment management, minority business enterprise, fund management services
Industry2 codes
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSAAALAG
Sustainable Private Markets (Impact PE/VC, Private Credit, Infrastructure)
Financial & Insurance/Asset & Wealth Management/Asset Management — ESG/Sustainable & Impact Investing
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Private Equity / Investment Management
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Private Equity Fund Management
TypeManaged Services
Description

Pharos generates revenue through management fees and carried interest from their private equity funds (Pharos Capital Partners I, II, III, III-A, and IV). They invest $25-$50 million per deal in healthcare companies serving underserved communities with the goal of achieving competitive, risk-adjusted returns through realized investments.

pharosfunds.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Others, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Pharos Capital Group is a physician-founded private equity firm that manages healthcare-focused investment funds (Pharos Capital Partners I, II, III, III-A, and IV), deploying $25 to $50 million of growth equity into established U.S.-based healthcare companies serving rural, urban, and tribal underserved communities. The firm generates returns for limited partners (foundations, family offices, institutional investors) through management fees and carried interest while building a portfolio of healthcare service and medical device companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Portfolio companies tripled average employee count during Pharos ownership
+1 more record
Product overview1 text field

Pharos Capital Group is a physician-founded healthcare private equity investment firm, not a product company. The firm operates as a platform of 15+ active portfolio companies across diverse healthcare sectors including telehealth (FasPsych), dialysis/renal services (Sanderling Renal Services, Renal Care 360°), behavioral health (The Family Treatment Network, Beacon Specialized Living, Seaside Healthcare), medical devices (RhythMedix cardiac monitoring), primary care (Complete Health), developmental disability services (Baroco Corporation), surgical services (Vantage Surgical Solutions), and healthcare staffing (Tribal Health, Medfinders). The portfolio includes both current investments and realized exits (TechLab, Aurora Imaging, MOTION PT Group). Each portfolio company operates as an independent healthcare service provider or medical device manufacturer serving underserved rural, urban, and tribal communities across the United States.

Product and service2 records
1Pharos Capital Partners IV Fund
CategoryPrivate Equity Fund
Description

Healthcare-focused private equity fund managed by Pharos Capital Group that deploys growth equity into established U.S.-based healthcare companies serving underserved communities. Available to foundations, family offices, and institutional investors as limited partner subscriptions.

2Pharos Capital Partners IV-A LP (RBIC)
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Long-established U.S. private equity firm focused exclusively on healthcare and technology, with a similar growth-equity orientation, mid-market deal sizes, and a portfolio spanning healthcare services and providers. Direct comparability to Pharos in mandate, fund structure, and LP base.

TypeDirect peer
Description

Growth equity firm focused on healthcare services and healthcare IT for middle-market companies. Comparable to Pharos in growth-equity mandate, healthcare-only focus, and partnership-style approach with founder-led businesses.

TypeDirect peer
Description

Chicago-based middle-market private equity firm with a strong healthcare, education, and essential-services focus and explicit impact-investing orientation. Closely comparable to Pharos in mission-driven healthcare PE, mid-market deal sizes, and underserved-community focus.

TypeDirect peer
Description

Healthcare-dedicated middle-market private equity firm with multiple funds, focused on healthcare services, pharma services, and medical products. Closely comparable to Pharos in fund size, healthcare-only mandate, and middle-market check size.

TypeDirect peer
Description

Healthcare-focused growth equity firm with multiple billion-dollar funds, investing in middle-market healthcare services, healthcare IT, and pharma services. Comparable in AUM scale, healthcare-only focus, and growth-equity deal sizes similar to Pharos's $25-50M range.

TypeDirect peer
Description

Healthcare-focused middle-market private equity firm investing in healthcare services, pharma, and medical devices. Directly comparable to Pharos in sector focus, fund size, and growth-equity orientation toward established healthcare companies.

TypeDirect peer
Description

Lower middle-market private equity firm exclusively focused on healthcare services, with control investments in founder-owned businesses. Comparable to Pharos in healthcare-only focus, founder/operator partnership model, and deal-size range.

TypeDirect peer
Description

Healthcare-dedicated middle-market private equity firm based in Chicago, focused on healthcare services and technology. Highly comparable to Pharos in fund size, sector exclusivity, and growth-stage investments.

TypeBroad incumbent
Description

Impact-focused private equity strategy within Bain Capital targeting measurable social and environmental outcomes alongside financial returns. Comparable to Pharos in impact-investing orientation and GIIN-aligned measurement, though backed by a much larger generalist platform.

TypeBroad incumbent
Description

Healthcare-dedicated growth equity strategy within KKR, a global mega-PE platform. Overlaps with Pharos in healthcare services and growth-stage mandate but operates at significantly larger fund size and broader LP base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries11 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A15 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment23 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharos Capital Partners

Healthcare Private Equity / Investment Managementpharosfunds.com

Pharos Capital Partners is a Dallas-based, physician-founded private equity firm that invests $25-$50 million per deal in U.S. healthcare companies serving rural, urban, and tribal underserved communities, managing $1.5B+ across five fund vintages and 53+ portfolio companies.

What Pharos Capital Partners does

Pharos Capital Partners is a Dallas-based, physician-founded private equity firm established in 1998 by Dr. Kneeland Youngblood, a former ER physician, and Bob Crants. Since 2013 the firm has operated as a dedicated healthcare-only investor, deploying $25 million to $50 million per transaction into established U.S. healthcare companies that serve rural, urban, and tribal underserved communities, with stated impact measured against GIIN IRIS+ healthcare metrics and six UN Sustainable Development Goals. The firm manages $1.5 billion+ in assets across five fund vintages (Pharos Capital Partners I, II, III, III-A, and IV/IV-A) and has invested in 53+ portfolio companies spanning behavioral health, dialysis and renal care, hospice and home health, primary care, medical devices, surgical services, and healthcare staffing, collectively operating 1,600+ care locations across all 50 states.

The firm's core "products" are its portfolio operating companies rather than a single technology platform; selected platforms include FasPsych (telepsychiatry), Sanderling Renal Services and Renal Care 360° (dialysis, tele-nephrology, and ML-assisted chronic kidney disease management), RhythMedix (wearable cardiac ECG monitoring with 4G connectivity), Complete Health (Medicare value-based primary care), Beacon Specialized Living Services and The Family Treatment Network (behavioral health and developmental disability services), THEMA Health Services (hospice, home health, palliative care), Vantage Surgical Solutions (mobile cataract surgery), and Tribal Health (staffing and consulting for Native American communities across 18 states). Pharos's primary technology asset at the firm level is a proprietary impact-measurement methodology verified by independent consultants against all 14 GIIN IRIS+ healthcare metrics; at the portfolio level, Renal Care 360° applies machine learning to identify vulnerable CKD and ESKD patients for early intervention.

Pharos generates revenue through conventional private equity fund economics, earning management fees on committed or invested capital across its fund vintages and carried interest on realized exits (notable realizations include MOTION PT Group in 2023 and TechLab, Inc. in 2022). The firm does not disclose specific fee rates or revenue figures; pricing and fund terms are negotiated bilaterally with limited partners including foundations, family offices, and institutional investors. Distribution is relationship-driven, supported by offices in Dallas, Nashville, Baltimore, and Silicon Valley, a dedicated investor portal, a corporate website, and a LinkedIn presence, with deal sourcing directed toward healthcare founders and operators and partnership engagement with payors, hospitals, health systems, and governmental agencies serving underserved populations.

Pharos Capital Partners firmographics

Firmographics
Name
Pharos Capital Partners
Legal name
Pharos Capital Group, LLC
Website
https://pharosfunds.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
11–50 employees
Short description
Pharos Capital Partners is a Dallas-based, physician-founded private equity firm that invests $25-$50 million per deal in U.S. healthcare companies serving rural, urban, and tribal underserved communities, managing $1.5B+ across five fund vintages and 53+ portfolio companies.
Ownership category
akta.pro rank

Pharos Capital Partners industry classification

Industry
Product category
Healthcare Private Equity / Investment Management
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSAAALAG
Sustainable Private Markets (Impact PE/VC, Private Credit, Infrastructure)
Financial & Insurance/Asset & Wealth Management/Asset Management — ESG/Sustainable & Impact Investing

Keywords

  • Healthcare private equity
  • Private equity funds
  • Healthcare investment management
  • Minority business enterprise
  • Fund management services

Where Pharos Capital Partners is headquartered

Location

Headquarters

HQ city
Dallas
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Pharos Capital Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others, Technology or R&D

Revenue model

  1. Private Equity Fund Management: Pharos generates revenue through management fees and carried interest from their private equity funds (Pharos Capital Partners I, II, III, III-A, and IV). They invest $25-$50 million per deal in healthcare companies serving underserved communities with the goal of achieving competitive, risk-adjusted returns through realized investments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Pharos Capital Partners product offering

Product offering

Core offering

Pharos Capital Group is a physician-founded private equity firm that manages healthcare-focused investment funds (Pharos Capital Partners I, II, III, III-A, and IV), deploying $25 to $50 million of growth equity into established U.S.-based healthcare companies serving rural, urban, and tribal underserved communities. The firm generates returns for limited partners (foundations, family offices, institutional investors) through management fees and carried interest while building a portfolio of healthcare service and medical device companies.

Product overview

Pharos Capital Group is a physician-founded healthcare private equity investment firm, not a product company. The firm operates as a platform of 15+ active portfolio companies across diverse healthcare sectors including telehealth (FasPsych), dialysis/renal services (Sanderling Renal Services, Renal Care 360°), behavioral health (The Family Treatment Network, Beacon Specialized Living, Seaside Healthcare), medical devices (RhythMedix cardiac monitoring), primary care (Complete Health), developmental disability services (Baroco Corporation), surgical services (Vantage Surgical Solutions), and healthcare staffing (Tribal Health, Medfinders). The portfolio includes both current investments and realized exits (TechLab, Aurora Imaging, MOTION PT Group). Each portfolio company operates as an independent healthcare service provider or medical device manufacturer serving underserved rural, urban, and tribal communities across the United States.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharos Capital Partners IV Fund Healthcare-focused private equity fund managed by Pharos Capital Group that deploys growth equity into established U.S.-based healthcare companies serving underserved communities. Available to foundations, family offices, and institutional investors as limited partner subscriptions.
  • Pharos Capital Partners IV-A LP (RBIC)

Quantifiable outcome

  • Portfolio companies tripled average employee count during Pharos ownership
  • +1 more outcomes

Companies that use Pharos Capital Partners

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Pharos Capital Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Pharos Capital Partners partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Pharos Capital Partners competitors and assessment

Company assessment

Direct peers

  • Welsh, Carson, Anderson & Stowe: Long-established U.S. private equity firm focused exclusively on healthcare and technology, with a similar growth-equity orientation, mid-market deal sizes, and a portfolio spanning healthcare services and providers. Direct comparability to Pharos in mandate, fund structure, and LP base.
  • Health Enterprise Partners: Growth equity firm focused on healthcare services and healthcare IT for middle-market companies. Comparable to Pharos in growth-equity mandate, healthcare-only focus, and partnership-style approach with founder-led businesses.
  • Vistria Group: Chicago-based middle-market private equity firm with a strong healthcare, education, and essential-services focus and explicit impact-investing orientation. Closely comparable to Pharos in mission-driven healthcare PE, mid-market deal sizes, and underserved-community focus.
  • Linden Capital Partners: Healthcare-dedicated middle-market private equity firm with multiple funds, focused on healthcare services, pharma services, and medical products. Closely comparable to Pharos in fund size, healthcare-only mandate, and middle-market check size.
  • New Mountain Capital: Healthcare-focused growth equity firm with multiple billion-dollar funds, investing in middle-market healthcare services, healthcare IT, and pharma services. Comparable in AUM scale, healthcare-only focus, and growth-equity deal sizes similar to Pharos's $25-50M range.
  • Avista Capital Partners: Healthcare-focused middle-market private equity firm investing in healthcare services, pharma, and medical devices. Directly comparable to Pharos in sector focus, fund size, and growth-equity orientation toward established healthcare companies.
  • Varsity Healthcare Partners: Lower middle-market private equity firm exclusively focused on healthcare services, with control investments in founder-owned businesses. Comparable to Pharos in healthcare-only focus, founder/operator partnership model, and deal-size range.
  • Cressey & Company: Healthcare-dedicated middle-market private equity firm based in Chicago, focused on healthcare services and technology. Highly comparable to Pharos in fund size, sector exclusivity, and growth-stage investments.

Broad incumbents

  • Bain Capital Double Impact: Impact-focused private equity strategy within Bain Capital targeting measurable social and environmental outcomes alongside financial returns. Comparable to Pharos in impact-investing orientation and GIIN-aligned measurement, though backed by a much larger generalist platform.
  • KKR Health Care Strategic Growth: Healthcare-dedicated growth equity strategy within KKR, a global mega-PE platform. Overlaps with Pharos in healthcare services and growth-stage mandate but operates at significantly larger fund size and broader LP base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Pharos Capital Partners social profiles

Digital presence

Pharos Capital Partners compliance and trust

Trust signal

Compliance3 records

Pharos Capital Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharos Capital Partners leadership team

Management profile

Number of profiles

Profiles7 records

Pharos Capital Partners subsidiaries and ownership

Company hierarchy

Subsidiaries11 records

Pharos Capital Partners funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharos Capital Partners M&A and investment

M&A and investment

M&A15 records

Investments23 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharos Capital Partners

What does Pharos Capital Partners do?

Pharos Capital Group is a physician-founded private equity firm that manages healthcare-focused investment funds (Pharos Capital Partners I, II, III, III-A, and IV), deploying $25 to $50 million of growth equity into established U.S.-based healthcare companies serving rural, urban, and tribal underserved communities. The firm generates returns for limited partners (foundations, family offices, institutional investors) through management fees and carried interest while building a portfolio of healthcare service and medical device companies.

Is Pharos Capital Partners a public or private company?

Pharos Capital Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Pharos Capital Partners founded?

Pharos Capital Partners was founded in 1998. It employs 11 to 50 people.

Where is Pharos Capital Partners based?

Pharos Capital Partners is headquartered in Dallas, United States, in the North America region.

How does Pharos Capital Partners make money?

One revenue line is on record: private Equity Fund Management.

Who are Pharos Capital Partners's main competitors?

Direct peers on record are Welsh, Carson, Anderson & Stowe, Health Enterprise Partners, Vistria Group, Linden Capital Partners, New Mountain Capital, Avista Capital Partners, Varsity Healthcare Partners and Cressey & Company. Broad incumbents are Bain Capital Double Impact and KKR Health Care Strategic Growth.

Does Pharos Capital Partners have an API?

No public API is recorded for Pharos Capital Partners.

What industry is Pharos Capital Partners in?

Pharos Capital Partners's product category is Healthcare Private Equity / Investment Management. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSAAALAG, Sustainable Private Markets (Impact PE/VC, Private Credit, Infrastructure). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePharos Capital-Backed Baroco Opens Agawam, MA Location, Expanding Access to Services for Individuals with Developmental DisabilitiesBaroco Corporation, a provider of day programs and support services for individuals with intellectual and developmental disabilities, celebrated the grand opening of a new facility in Agawam, Massachusetts, expanding its operations to six facilities serving more than 330 people across Massachusetts and Connecticut. Pharos Capital Group, which first invested in Baroco in 2023, is supporting this expansion as part of its strategy to invest in healthcare companies that expand access to care in underserved markets. The new Agawam location targets the highest acuity and most fragile members of the local community.WewillcurePrivate Equity Pours Billions Into Home Healthcare Amid Rising DemandPrivate equity firms are accelerating investments in home-based healthcare, acquiring companies such as Help at Home, Senior Helpers, and MedTec Healthcare to consolidate a sector projected to grow 8.5 percent annually and deliver 30 percent cost savings compared to institutional care. Waud Capital Partners, Pharos Capital Group, Centerbridge Partners, and the Vistria Group are among the active investors executing multi-deal consolidation strategies across the United States. However, proposed cuts to Medicare and Medicaid reimbursement under a potential second Trump administration pose a significant threat to the financial models underpinning these investments, risking reduced margins and increased risk for PE-backed providers.GlobeNewswireHark Capital provides $50 million NAV facility to Pharos Capital GroupHark Capital closed a $50 million NAV facility with Pharos IV-A, a healthcare-focused private equity fund. Proceeds will support new and existing investments in Pharos' portfolio. The deal marks the third financing facility between the two firms.GlobeNewswireHark Capital provides $50 million NAV facility to Pharos Capital GroupHark Capital closed a $50 million NAV facility with Pharos IV-A, a healthcare-focused private equity fund. Proceeds will support new and existing investments in Pharos' portfolio. The deal marks the third financing facility between the two firms.LinkedInAI in Private Equity: Beyond the Hype Actual Internal Operational Efficiency and Portfolio Company Value CreationA comprehensive industry report examining how private equity firms are integrating AI across internal operations and portfolio companies, revealing that while 78% of organizations adopted AI in 2024 (up from 55% in 2023), fewer than 10% report achieving expected ROI—a phenomenon McKinsey calls the 'GenAI Paradox.' The report documents case studies from firms including Sentinel Capital Partners (80% reduction in NDA review time), Pharos Capital Group (40 hours saved in SEC exam response), and portfolio companies achieving significant gains such as a metal manufacturer projecting $6.5 million in annual savings and a healthcare platform delivering $2 million in net new annual revenue per 10,000 patient discharges.ThemiddlemarketPharos Capital Makes Majority Investment in RhythMedixPharos Capital has made a majority investment in RhythMedix, a healthcare technology company founded in 2013 that specializes in remote cardiac monitoring solutions. The transaction represents a strategic financial backing for the firm's efforts to enhance patient and clinician experiences in cardiac care.American City Business JournalsPharos Capital sells majority stake in Motion PT Group to Confluent HealthPharos Capital Group has sold its majority stake in Motion PT Group to Confluent Health. The transaction highlights Confluent Health's expanding portfolio and strategic growth in the healthcare sector. This acquisition is expected to enhance Confluent Health's service offerings in physical therapy.AxiosScoop: Physical therapy M&A warms up: THL's ProPT, Pharos' Motion PTTHL Partners' ProPT is in a Jefferies-run auction with bids expected in early August, while Pharos Capital Group's Motion PT Group has launched a sale process via Livingstone Partners. ProPT's trailing EBITDA is $22-25 million, and Motion PT expects $18 million in 2022 pro forma adjusted EBITDA. The Northeast physical therapy market remains fragmented, with more single-digit EBITDA assets anticipated to come to market.